HER2-positive breast cancer patients could now benefit from Herceptin SC injection
 

From today, patients with a very aggressive form of breast cancer known as HER2-positive, could benefit from a new faster, more efficient delivery method of Herceptin. The subcutaneous injection, given just beneath the skin, can be completed in 2-5 minutes, compared to the traditional, relatively time-consuming 30-90 minute intravenous infusion.

More...